Fulcrum Therapeutics Plans About $7 Million Asset Sale To Add To Merger Dividend

The buyer's payment is expected to count toward Fulcrum's net cash under its proposed merger with Slate Medicines.

Share
Fulcrum Therapeutics Plans About $7 Million Asset Sale To Add To Merger Dividend

Fulcrum Therapeutics, which develops small-molecule drugs for genetically defined rare diseases, agreed to sell early-stage drug assets for approximately $7 million in cash. The company said in a Thursday SEC filing that it expects the proceeds to increase the cash dividend stockholders would receive through its proposed merger with Slate Medicines.

Sale Cash Feeds The Dividend

Fulcrum and Slate, its proposed merger partner, signed the sale agreement Saturday with an unaffiliated pharmaceutical company. The assets concern fetal hemoglobin, a form of the oxygen-carrying protein normally produced before birth.

Fulcrum expects the buyer to deposit the payment into escrow before the merger closes. That cash would be credited toward Fulcrum's net cash under the merger agreement, increasing the amount available for the expected cash dividend.

The asset sale depends on the merger being completed. If the merger agreement is terminated, the sale would instead require any necessary approvals.

A Rare-Disease Pipeline In Development

Fulcrum's lead drug candidate, pociredir, is an oral treatment designed to raise fetal hemoglobin in people with sickle cell disease, a genetic red-blood-cell disorder. The company has completed dosing in an early-stage trial involving adults.

Its research also seeks cellular targets that could alter gene expression. Fulcrum has an early-stage cancer candidate, FTX-6274, alongside its rare-disease work.

The company has no drug approved for sale. It relies on outside manufacturers to produce its candidates and owns no manufacturing facilities.

Slate Merger Awaits Stockholders

Fulcrum's agreement to combine with Slate dates to August 16, 2026. The asset sale therefore sits within an existing merger plan, with its expected proceeds entering the cash calculation used for that transaction.

The merger registration statement became effective on November 4, and Fulcrum filed a proxy statement and prospectus dated November 4 for stockholders evaluating the combination. The proposed merger still requires their approval.

For Fulcrum holders, the expected larger cash distribution remains tied to completion of the proposed Slate merger.

Sources

More on Fulcrum Therapeutics

All Fulcrum Therapeutics (FULC) coverage →